Summary:
Researchers at UC San Francisco have identified 16 brain-aging molecules in blood that spike during the menopause transition, tracked by hormonal flux rather than chronological age. In older women, elevated levels of these same midlife biomarkers correlated with poorer cognitive performance and a 15% increase in Alzheimer’s disease risk decades later.
Key Facts:
- Hormone-Driven, Not Just Aging: Shifts in 16 circulating blood molecules mapped directly to changing levels of estradiol and follicle-stimulating hormone (FSH) using the STRAW+10 staging tool, rather than chronological age alone.
- Predictive Decades Later: In cohorts totaling nearly 12,000 older women, individuals exhibiting the highest levels of these 16 biomarkers displayed worse memory performance and a 15% increased risk of developing Alzheimer’s disease.
- Persistent Inflammatory Signature: Vasomotor symptoms like night sweats and hot flashes were tied to sharp increases in systemic inflammatory markers during menopause, leaving a molecular trace that persisted into late life.
Source: University of California, San Francisco (UCSF)
Hot flashes, sleep disruption, anxiety, and sudden cognitive lapses, frequently described by patients as “brain fog”, are hallmark complaints of the menopause transition. While two-thirds of all Alzheimer’s disease diagnoses occur in women, researchers have struggled to explain this disparity solely through women’s longer average lifespans.
Because the silent, underlying neuropathology of Alzheimer’s begins accumulating decades before clinical memory impairment emerges, researchers have long hypothesized that the endocrine transition of midlife might represent a critical biological pivot point.
In a study published in Nature Medicine, scientists at the UC San Francisco Fein Memory and Aging Center and the University of Toronto demonstrated that the menopausal transition leaves a distinct signature of 16 circulating blood proteins associated with accelerated brain aging and long-term neurodegeneration.
“We don’t think that menopause is directly causing dementia,” said Kaitlin Casaletto, Ph.D., an associate professor at the UCSF Fein Memory and Aging Center and co-senior author of the study. “But it’s possible that we may be able to predict a woman’s risk for dementia decades later by the levels of these molecules around menopause.”
Mapping the Molecular Dynamics of Menopause
Rather than treating menopause as a binary event defined only by the final menstrual period, the investigative team evaluated the years-long endocrine flux using the STRAW+10 (Stages of Reproductive Aging Workshop + 10) staging criteria.
The researchers analyzed 80 women across their 40s and 50s, using multiplex assays measuring more than 100 blood-borne proteins known to reflect neurodegenerative, inflammatory, and neurovascular processes.
From this panel, 16 molecules showed coordinated shifts across reproductive stages:
- Estradiol Drop and Inflammation: Declines in circulating estradiol correlated with an elevation in systemic inflammatory proteins.
- FSH Elevation and Alzheimer’s Cascades: Parallel spikes in follicle-stimulating hormone (FSH) were accompanied by increases in proteins tied directly to amyloid- and tau-related Alzheimer’s biology.
These molecular patterns were replicated in a large cohort of more than 2,800 women from the UK Biobank dataset.
Long-Term Cognitive Repercussions
To determine whether these midlife changes carried long-term neurological consequences, the authors analyzed archival data from four longitudinal cohorts encompassing nearly 12,000 women in their 60s and 70s.
Older women exhibiting the highest concentrations of these 16 blood-based markers demonstrated significantly poorer memory and thinking abilities, alongside a 15% elevated risk of developing Alzheimer’s disease.
The study also uncovered a direct connection to clinical menopause symptoms: women reporting severe night sweats exhibited the sharpest elevations in inflammatory proteins. This inflammatory signature remained discernible decades later in older women who remembered experiencing severe vasomotor symptoms during midlife.
A Critical Window for Early Intervention
Intriguingly, preliminary analysis of midlife men revealed a similar molecular fingerprint, but one that developed gradually over decades rather than through the abrupt endocrine transition seen in women. This indicates that menopause may act as an accelerated biological aging event.
“Menopause is a normal physiological process that every person who has ovaries who lives long enough will go through,” noted first author Madeline Wood Alexander of the University of Toronto. “We don’t want it to be viewed as a bad thing, but as an opportunity to better understand and maybe modify the biology of brain aging in women.”
The research team aims to refine this 16-molecule profile into a routine clinical blood screen, functioning much like a midlife lipid panel for cardiovascular disease. To expand this research, Casaletto is launching the Longitudinal Menopause Project, which will track women through the complete transition using high-frequency blood draws, multimodal neuroimaging, wearable monitors, and digital cognitive testing.
Funding: National Institutes of Health (R01AG032289, R01AG048234, R01AG063843, RF1AG096165, RF1AG096477, P30AG062422, R01AG072475, K23AG090757, AG027161, UE5NS070680, K23AG084883, and U19AG024904). For all funding, see the paper.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this Alzheimer’s disease Research:
- Media Contact: Victoria Colliver
- Source: UCSF
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Nature Medicine (Sept 22, 2026). “Blood proteomics of menopause map to brain aging and dementia risk.” Authors: Madeline Wood Alexander, Jennifer S. Rabin, Michelle Caunca, Allesandra Iadipaolo, Louisa Cornelis, Ria Warrier, Keenan A. Walker, Nina Miolane, Veronica Augustina Bot, Brendan Wood, Hamilton Se-Hwee Oh, Tony Wyss-Coray, Albert Pham, Julia Borger, Valentina Diaz, Emily W. Paolillo, Joel Kramer, Laura Pritschet, Caitlin Taylor, Matthew S. Panizzon, Ramiro Eduardo Rea Reyes, Marisa N. Denkinger, Nicholas J. Ashton, Sterling C. Johnson, Emily G. Jacobs, Rowan Saloner & Kaitlin B. Casaletto.
- DOI: 10.1038/s41591-026-04648-4
Abstract
Blood proteomics of menopause map to brain aging and dementia risk
Menopause is a hallmark process in biological aging that has been implicated in later neurodegenerative risk, but the pathways underlying this connection remain unclear.
Here we used blood proteomics data from several cohorts to identify biological changes associated with menopause and its links to brain aging. In n = 80 rigorously staged (STRAW+10) pre-, peri- and postmenopausal women (aged 43–58 years) with serum NULISAseq proteomics, we show that spontaneous menopause is characterized by dysregulation in inflammatory, synaptic, metabolic and Alzheimer’s disease biologic processes, which tracked more strongly with hormones than with age.
Validation analyses in age-matched pre-/peri- and postmenopausal women (n = 2,814) with plasma Olink proteomics replicated the observed proteomic shifts and revealed broader menopause-related upregulation of inflammatory and catabolic processes plus accelerated organ and cell aging, including brain aging.
In four independent cohorts of older women (average age, 60.7–72.1 years; total n = 11,925), higher menopause proteomic scores associated consistently with cognitive aging and dementia risk. The molecular signatures of menopause may inform the selection of biomarkers or therapeutic targets for brain health in midlife women.
